Saizen® ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 78 | Hypopituitarism | 12 |
78. Hypopituitarism
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01806298 (ClinicalTrials.gov) | June 2013 | 5/3/2013 | An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) | Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) | Adult Growth Hormone Deficiency | Drug: Saizen® solution for injection (referred as Saizen®) | Merck KGaA | NULL | Completed | 18 Years | 65 Years | All | 78 | Phase 4 | Australia;Germany;Sweden;United Kingdom;Czech Republic |
| 2 | EUCTR2012-004263-47-CZ (EUCTR) | 13/05/2013 | 05/03/2013 | Exploration if Saizen marketed solution for injection induces an immunogenic reaction | Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD). - Saizen, Phase 4 study in Growth Hormone Deficiency | Adult Growth Hormone Deficiency MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: SAIZEN INN or Proposed INN: Somatropin Other descriptive name: SOMATROPIN | Merck KGaA | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 4 | Czech Republic;Australia;Germany;United Kingdom;Sweden | ||
| 3 | EUCTR2012-004263-47-DE (EUCTR) | 03/04/2013 | 25/02/2013 | Exploration if Saizen marketed solution for injection induces an immunogenic reaction | Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) - Saizen, Phase 4 study in Growth Hormone Deficiency | Adult Growth Hormone Deficiency MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: SAIZEN INN or Proposed INN: Somatropin Other descriptive name: SOMATROPIN | Merck KGaA | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 4 | Czech Republic;Australia;Germany;United Kingdom;Sweden | ||
| 4 | EUCTR2012-004263-47-SE (EUCTR) | 06/03/2013 | 14/01/2013 | Exploration if Saizen marketed solution for injection induces an immunogenic reaction | Open-label, single-arm, phase IV, multicenter trial to explore theimmunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) | Adult Growth Hormone Deficiency MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: SAIZEN | Merck KGaA | NULL | Not Recruiting | Female: yes Male: yes | 77 | Phase 4 | Czech Republic;Australia;Germany;United Kingdom;Sweden | ||
| 5 | EUCTR2012-004263-47-GB (EUCTR) | 01/03/2013 | 08/01/2013 | Exploration if Saizen marketed solution for injection induces an immunogenic reaction | Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset - Saizen, Phase 4 study in Growth Hormone Deficiency | Adult Growth Hormone Deficiency MedDRA version: 17.1;Level: PT;Classification code 10056438;Term: Growth hormone deficiency;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: SAIZEN | Merck KGaA | NULL | Not Recruiting | Female: yes Male: yes | 77 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | Czech Republic;Australia;Germany;United Kingdom;Sweden | ||
| 6 | NCT01494779 (ClinicalTrials.gov) | March 2013 | 28/11/2011 | Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A. | GH Deficiency (GHD);Growth Retardation | Drug: Somatropin | L.A.L Clinica Pesquisa e Desenvolvimento Ltda. | NULL | Not yet recruiting | 18 Years | 32 Years | Male | 32 | Phase 1 | Brazil | |
| 7 | NCT01237340 (ClinicalTrials.gov) | October 2010 | 5/11/2010 | Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study | A Phase IIIb, Open-label, Single-arm, Multicenter Study to Assess the Immunogenicity of the Recombinant-Human Growth Hormone (r-hGH) Liquid Multidose Formulation (Saizen® Solution for Injection) When Administered to Male and Female Adults With Documented Growth Hormone Deficiency (GHD) | Growth Hormone Deficiency (GHD) | Drug: Saizen® | EMD Serono | NULL | Terminated | 18 Years | 60 Years | All | 59 | Phase 3 | United States |
| 8 | NCT01187550 (ClinicalTrials.gov) | March 2007 | 22/8/2010 | Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® | A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® | Dwarfism, Pituitary | Drug: Recombinant human growth hormone (r-hGH) | Merck KGaA | Merck Serono Co., Ltd., China | Completed | N/A | N/A | All | 214 | Phase 4 | NULL |
| 9 | NCT00256126 (ClinicalTrials.gov) | May 31, 2005 | 18/11/2005 | Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® | A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children Treated With SAIZEN® | Growth Hormone Deficiency;Turner Syndrome | Drug: Saizen | Merck KGaA, Darmstadt, Germany | NULL | Completed | 2 Years | 16 Years | All | 318 | Phase 4 | Argentina;Australia;Austria;Canada;France;Germany;Italy;Norway;Russian Federation;Singapore;Spain;Sweden;United Kingdom |
| 10 | NCT00109733 (ClinicalTrials.gov) | January 2005 | 2/5/2005 | Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency | A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS) | Childhood-onset Growth Hormone Deficiency;Pituitary Dwarfism | Biological: recombinant human growth hormone | EMD Serono | NULL | Completed | 13 Years | 25 Years | All | 31 | Phase 3 | United States |
| 11 | NCT01157793 (ClinicalTrials.gov) | September 2003 | 6/7/2010 | A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood | A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in GHD Subjects During the Transition Phase From Childhood to Adulthood | Dwarfism;Growth Hormone Deficiency | Drug: r-hGH | Merck KGaA | NULL | Completed | 14 Years | 25 Years | Both | 34 | Phase 4 | NULL |
| 12 | EUCTR2015-001569-20-Outside-EU/EEA (EUCTR) | 06/07/2015 | Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® | A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® | Dwarfism, Pituitary MedDRA version: 18.0;Level: PT;Classification code 10013883;Term: Dwarfism;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: Saizen | Merck Serono Co., Ltd. | NULL | NA | Female: yes Male: yes | 214 | Phase 4 | China |